LENZ Therapeutics: Telehealth and TV Ads Drive 50% Growth; CEO Transition Nuance
LENZ Therapeutics' Q3 2026 call centered on a decisive pivot toward a 'consumer-led' commercial model, following a quarter where telehealth and national TV advertising drove a 50% sequential increase in product revenue. Management provided critical color on the efficiency of the telehealth channel, which accounted for over half of incremental script growth and significantly compressed the sales cycle from weeks to days. While the CEO transition and a 50% reduction in projected 2027 operating expenses dominated t...
What changed on the call
Incremental information and investor implications beyond the release.
- Telehealth Velocity
The telehealth channel, launched in July, contributed more than 50% of the incremental scripts in Q3. Management noted that the response time from a consumer seeing a TV ad to filling a prescription via telehealth is measured in days, compared to a 4-to-6 week cycle for traditional in-office visits.
This validates the 'consumer-led' pivot; telehealth provides a much higher and faster conversion rate for DTC marketing spend than the traditional physician-detailing model. - Strategic Reorganization and Headcount
The company is reducing its workforce to approximately 40 employees. The goal is to align the cost structure with a model where 70% of the $70-75M projected 2027 OpEx is dedicated to consumer-driven marketing rather than a large field sales force.
This significantly lowers the break-even bar and shifts the company from a high-touch pharma model to a leaner, direct-to-consumer health model. - Refill and Consumption Patterns
Management shared that in the e-pharmacy channel, approximately 60% of patients purchase more than a one-month supply initially, and the average patient is consuming more than five packs per year.
High stickiness and predictable consumption patterns improve the long-term value (LTV) of acquired customers, supporting the increased DTC spend.
Guidance and model clarifications
Analyst Q&A
Telehealth vs. Traditional Channels
TD Cowen, Citi, William BlairManagement emphasized that while telehealth is the fastest grower, they are still seeing growth in traditional retail pharmacies. However, telehealth is the primary engine for 'new-to-brand' patients who were not previously in the eye care system.
Investor read-through: Telehealth is expanding the total addressable market by capturing consumers who avoid the friction of an in-person eye exam.
CEO Search Process
Bank of AmericaThe Board has initiated a formal search for a permanent CEO. Dan Chevallard is considered a key candidate, but the company is not committing to a specific timeline for a final appointment.
Investor read-through: There is a high likelihood of internal promotion if Dan executes well on the restructuring in the coming months.
Risks and watch items
- Data Accuracy Discrepancies
Management noted that Symphony data (showing 94% market share) is more accurate than IQVIA data for this category, which they claim has only about 70% accuracy. Investors should be wary of third-party data volatility.
- Execution Risk in Reorg
Reducing headcount to 40 people while attempting to maintain 90% brand awareness among ECPs (Eye Care Professionals) relies heavily on digital marketing replacing physical reps.
Management tone
- CEO Succession
Eef stated the transition was to 'devote more time to other passions' and expressed full confidence in Dan Chevallard’s ability to lead the next phase.
Management was careful to frame Eef Schimmelpennink’s departure as a deeply personal decision rather than a reflection of company performance. - Commercial Strategy
Sean Wilson noted they can now 'very easily monitor where advertising is working' by correlating TV spots directly to telehealth traffic within 48 hours.
Aggressive and data-driven. Management is no longer guessing which channels work; they are doubling down on the TV-to-Telehealth pipeline.
Reinforced on the call
- Market Leadership
Viz remains the #1 selling presbyopia eye drop in the U.S. with 94% market share per Symphony data.
- Global Expansion
11 regulatory submissions are currently under review internationally, with multiple approvals expected in the coming months.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Earnings call webcastFollow LENZ in real time
Get material earnings, filing, IR, and earnings-call alerts by email.